Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM, June 4, 2013 /PRNewswire/ --
OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company’s patent estate for this unmet medical need.
“We are continuously working to further strengthen the world-wide rights for our lead product Oxabact®" for treatment of Primary Hyperoxaluria, an orphan disease,” says Elisabeth Lindner, CEO of OxThera. “The Japanese rights are important additions to our already granted patents in the EU and the US. Japan is an important market for hyperoxaluria” Elisabeth Lindner continues.
OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in seven patent families with approximately eighty applications filed. The new granted Japanese patents have numbers 4996780, 5047190 and 5203217.
Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently pursuing a complete Oxabact® clinical development plan in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.
About Primary Hyperoxaluria
Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.
Oxabact® holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.
About OxThera
OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in Secondary Hyperoxaluria. OxThera operates through the head office in Stockholm, Sweden, and its subsidiary OxThera Inc. in Alachua, Florida, USA.
For further information, please contact Elisabeth Lindner, CEO of OxThera AB, Phone +46-8-660-02-23.
Help employers find you! Check out all the jobs and post your resume.
